Elusys Therapeutics is committed to developing new biotherapeutic products that dramatically improve treatment of life-threatening infectious disease.

 

 

 

ANTHIM
Effective treatment for anthrax infection from biowarfare attacks

learn more >>

 

 

 

ETI-211
Heteropolymer (HP) Antibody for treatment of Staph Aureus infections

learn more >>

 

 

Heteropolymer Antibodies
How they work

learn more >>

 

NEWS

June 16th, 2009
Elusys Therapeutics and Lonza Enter Into Manufacturing Agreement
read more >>

Elizabeth Posillico, PhD inducted into NJ’s High Tech Hall of Fame
read more >>

April 22nd, 2008
Elusys’ Anthim™ Dramatically Improves Survival of Animals Treated...
read more >>

LEARN MORE ABOUT...

Our product pipeline
New approaches for the treatment of infectious disease
learn more >>

Working at Elusys
A dynamic, creative environment to advance your career
learn more >>